Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01229865 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
A Phase 2 study of Differential Thyroid Cancer, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT01229865: Completed Phase 2 study of Differential Thyroid Cancer, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
NCT01229865 is a Phase 2 study of Differential Thyroid Cancer that has completed, run by Vascular Biogenics Ltd. operating as VBL Therapeutics. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01229865, a Phase 2 study of Differential Thyroid Cancer, has completed, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.
Conditions Studied
Interventions
- DRUG VB-111
Study Locations (3)
Florida
- Mayo Clinic - Jacksonville
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
What the finished NCT01229865 record still lists
NCT01229865 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Differential Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which VB-111 is the first listed.
NCT01229865 reports a single indexed study location in Florida, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01229865 about?
NCT01229865 is a clinical study titled "Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer". The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.
What is the current status of trial NCT01229865?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2010-12. Estimated completion is 2016-06.
What conditions does trial NCT01229865 study?
This clinical trial studies the following conditions: Differential Thyroid Cancer.
What interventions are being tested in trial NCT01229865?
The interventions under investigation include: VB-111 (DRUG).
Who is sponsoring clinical trial NCT01229865?
This trial is sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01229865 being conducted?
This trial has 3 study locations across Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01229865's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia